DexCom, Inc. (NASDAQ:DXCM) Stock Position Increased by Natixis

Natixis lifted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 25.0% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,000 shares of the medical device company’s stock after purchasing an additional 1,600 shares during the period. Natixis’ holdings in DexCom were worth $1,110,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of DXCM. HB Wealth Management LLC grew its stake in DexCom by 65.5% in the fourth quarter. HB Wealth Management LLC now owns 5,001 shares of the medical device company’s stock valued at $621,000 after purchasing an additional 1,980 shares in the last quarter. CVA Family Office LLC bought a new position in DexCom during the fourth quarter worth about $100,000. Pacer Advisors Inc. lifted its stake in DexCom by 7.9% during the fourth quarter. Pacer Advisors Inc. now owns 55,174 shares of the medical device company’s stock worth $6,847,000 after purchasing an additional 4,056 shares during the period. Washington Trust Advisors Inc. lifted its stake in DexCom by 120.6% during the fourth quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company’s stock worth $44,000 after purchasing an additional 193 shares during the period. Finally, Inscription Capital LLC bought a new position in shares of DexCom in the fourth quarter valued at approximately $248,000. 97.75% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Stifel Nicolaus dropped their price objective on shares of DexCom from $145.00 to $132.00 and set a “buy” rating for the company in a research report on Friday, July 12th. Morgan Stanley cut their price objective on shares of DexCom from $132.00 to $120.00 and set an “equal weight” rating on the stock in a research report on Monday, July 15th. Canaccord Genuity Group reissued a “buy” rating and set a $145.00 price target on shares of DexCom in a research report on Tuesday. Raymond James upped their target price on shares of DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a report on Friday, April 26th. Finally, UBS Group upped their price target on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $139.33.

Insider Buying and Selling

In related news, EVP Sadie Stern sold 427 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $115.05, for a total transaction of $49,126.35. Following the sale, the executive vice president now owns 75,877 shares in the company, valued at approximately $8,729,648.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Bridgette P. Heller sold 1,000 shares of the stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $113.55, for a total value of $113,550.00. Following the completion of the transaction, the director now owns 25,349 shares of the company’s stock, valued at approximately $2,878,378.95. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Sadie Stern sold 427 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $115.05, for a total transaction of $49,126.35. Following the completion of the transaction, the executive vice president now directly owns 75,877 shares of the company’s stock, valued at approximately $8,729,648.85. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 4,112 shares of company stock worth $480,861. Corporate insiders own 0.30% of the company’s stock.

DexCom Price Performance

Shares of NASDAQ DXCM traded down $4.09 during trading hours on Thursday, hitting $107.85. 10,917,461 shares of the stock were exchanged, compared to its average volume of 2,908,776. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.53 and a current ratio of 2.90. The company has a market cap of $42.89 billion, a PE ratio of 72.19, a price-to-earnings-growth ratio of 2.74 and a beta of 1.16. The company’s fifty day simple moving average is $117.11 and its two-hundred day simple moving average is $124.40. DexCom, Inc. has a 1-year low of $74.75 and a 1-year high of $142.00.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.05. The business had revenue of $921.00 million for the quarter, compared to analyst estimates of $911.20 million. DexCom had a net margin of 16.82% and a return on equity of 31.01%. On average, sell-side analysts predict that DexCom, Inc. will post 1.78 EPS for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.